title: Crohn's disease onset in an HIV/hepatitis C virus co-infected woman taking pegylated interferon alpha-2b plus ribavirin.
authors.forename: Marco
authors.initials: M
authors.lastname: Bongiovanni
authors.forename: Roberto
authors.initials: R
authors.lastname: Ranieri
authors.forename: Stefano
authors.initials: S
authors.lastname: Ferrero
authors.forename: Francesca
authors.initials: F
authors.lastname: Casanova
authors.forename: Antonella d'Arminio
authors.initials: Ad
authors.lastname: Monforte
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D003424:Crohn Disease / Q000209:etiology*; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D015497:HIV-1; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b